Importantly, IFN-DC loaded ex vivo or in vivo with whole tumor cells offer the advantage of eliciting immunity against the entire collection of antigens expressed by the tumor, enabling a wider and more efficient antitumor immune response. This evidence concerns the gene IFNA1 and neoplasm.